AVENIO ctDNA Expanded Kit V2

For Research Use Only. Not for use in diagnostic procedures.

AVENIO ctDNA expanded kit

Overview

 

The AVENIO ctDNA Expanded Kit V2 is a next-generation sequencing (NGS) liquid biopsy assay with a 77 gene panel containing genes in U.S. National Comprehensive Cancer Network (NCCN) Guidelines1 and emerging cancer biomarkers. It is a pan-cancer assay that’s specially optimized for lung cancer and colorectal cancer (CRC) research.

 

Features and Benefits

 

  • Contains genes in the U.S. National Comprehensive Cancer Network (NCCN) Guidelines1 and emerging cancer biomarkers
  • All four mutation classes (SNVs, indels, fusions and CNVs) in a single assay
  • Exceptional analytical performance supported by integrated digital error suppression (iDES) strategies combining molecular barcodes with in silico error suppression techniques2,3
  • Includes reagents, bioinformatics and software
  • Streamlined, end-to-end workflow from extraction to analysis and reporting in five days

Exceptional Performance3

AVENIO ctDNA expanded kit metrics
AVENIO ctDNA expanded kit gene list
A portfolio of NGS liquid biopsy assays

The AVENIO ctDNA Expanded Kit V2 is one of three assays in the AVENIO ctDNA research assay portfolio. Learn more about the 17-gene AVENIO ctDNA Targeted Kit V2 for guideline-driven tumor profiling or the 197-gene AVENIO ctDNA Surveillance Kit V2 for longitudinal tumor burden monitoring.

To ask a question or to speak to a Roche representative
Contact us

References

  1. National Comprehensive Cancer Network. Accessed August 2, 2023.
  2. Newman AM, Bratman SV, To J, et al. An ultrasensitive method for quantitating circulating tumor DNA with broad patient coverage. Nature Medicine. 2014;20(5):548–554 doi:10.1038/nm.3519
  3. Data on file with Roche.

Specifications

  • Panel size

    192 kb

  • Sample size

    4 ml of plasma

  • cfDNA input

    10-50 ng

  • Reactions per kit

    16

  • Turn-around time

    5 days from extraction to results

To ask a question or to speak to a Roche representative
Contact us